Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14237
Abstract: e14237 Background: Targeting myeloid-derived suppressor cells (MDSCs), key mediators of intrinsic and adaptive immune resistance, remains a significant challenge in kidney cancer immunotherapy. One potential driver of MDSC mediated tumor immunosuppression is the cytokine interleukin-1… read more here.
Keywords: therapy; pd1; combination; pd1 il1 ... See more keywords